NCT00606138View on ClinicalTrials.gov

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

ranibizumab

One 0.5 mg intravitreal injection

PROCEDURE

Laser photocoagulation

panretinal photocoagulation (up to 500 300-500 um laser spots)

Trial Locations (1)

60612

Rush University Medical Center, Chicago

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Rush University Medical Center

OTHER